Key result
AT1A receptor deficiency in MRL-Faslpr/lpr mice significantly reduced mean survival from 162 to 117 days and accelerated kidney injury due to activation of glomerular AT1B receptors.
Why the study?
Does AT1A receptor deficiency protect against autoimmune nephritis in MRL-Faslpr/lpr mice?
Does AT1A receptor deficiency protect against autoimmune nephritis in MRL-Faslpr/lpr mice?
In a murine model of autoimmune nephritis, AT1A receptor deficiency paradoxically accelerated renal injury and mortality due to compensatory activation of glomerular AT1B receptors.
Answers are grounded in this paper and cite their sources.
AT1A deficiency worsens outcomes in this murine nephritis model; challenges presumed protective effects and leaves open AT1B compensation for targeted study.
Studies in humans and animal models indicate a key contribution of angiotensin II to the pathogenesis of glomerular diseases. To examine the role of type 1 angiotensin (AT1) receptors in glomerular inflammation associated with autoimmune disease, we generated MRL-Faslpr/lpr (lpr) mice lacking the major murine type 1 angiotensin receptor (AT1A); lpr mice develop a generalized autoimmune disease with glomerulonephritis that resembles SLE. Surprisingly, AT1A deficiency was not protective against disease but instead substantially accelerated mortality, proteinuria, and kidney pathology. Increased disease severity was not a direct effect of immune cells, since transplantation of AT1A-deficient bone marrow did not affect survival. Moreover, autoimmune injury in extrarenal tissues, including skin, heart, and joints, was unaffected by AT1A deficiency. In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression is especially prominent in the renal glomerulus within podocytes. Further, expression of renin was enhanced in kidneys of AT1A-deficient lpr mice, and they showed evidence of exaggerated AT1B receptor activation, including substantially increased podocyte injury and expression of inflammatory mediators. Administration of losartan, which blocks all type 1 angiotensin receptors, reduced markers of kidney disease, including proteinuria, glomerular pathology, and cytokine mRNA expression. Since AT1A-deficient lpr mice had low blood pressure, these findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to accelerate renal injury and inflammation in the absence of hypertension.
No takes yet. Share an insight, caveat, or question.
Crowley et al. (2009) studied Autoimmune nephritis (SLE model) (n=85). AT1A receptor deficiency vs. Wild-type AT1A (lpr controls) was evaluated on Mean duration of survival (days) (p=0.001). AT1A receptor deficiency in MRL-Faslpr/lpr mice significantly reduced mean survival from 162 to 117 days and accelerated kidney injury due to activation of glomerular AT1B receptors.
Synapse has enriched 10 related papers. Consider them for comparative context: